These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 11044356)

  • 1. Low expression of bcl-2 in Brca1-associated breast cancers.
    Freneaux P; Stoppa-Lyonnet D; Mouret E; Kambouchner M; Nicolas A; Zafrani B; Vincent-Salomon A; Fourquet A; Magdelenat H; Sastre-Garau X
    Br J Cancer; 2000 Nov; 83(10):1318-22. PubMed ID: 11044356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between BRCA1 expression and apoptosis-related biological parameters in sporadic breast carcinomas.
    Yang Q; Yoshimura G; Nakamura M; Nakamura Y; Suzuma T; Umemura T; Mori I; Sakurai T; Kakudo K
    Anticancer Res; 2002; 22(6B):3615-9. PubMed ID: 12552965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes.
    Loman N; Johannsson O; Bendahl PO; Borg A; Fernö M; Olsson H
    Cancer; 1998 Jul; 83(2):310-9. PubMed ID: 9669814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women.
    Noguchi S; Kasugai T; Miki Y; Fukutomi T; Emi M; Nomizu T
    Cancer; 1999 May; 85(10):2200-5. PubMed ID: 10326698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
    Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients.
    de Bock GH; Tollenaar RA; Papelard H; Cornelisse CJ; Devilee P; van de Vijver MJ
    Br J Cancer; 2001 Nov; 85(9):1347-50. PubMed ID: 11720473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
    Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
    Birgisdottir V; Stefansson OA; Bodvarsdottir SK; Hilmarsdottir H; Jonasson JG; Eyfjord JE
    Breast Cancer Res; 2006; 8(4):R38. PubMed ID: 16846527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between the expression of apoptosis-related bcl-2 and p53 oncoproteins and the carcinogenesis and progression of breast carcinomas.
    Zhang GJ; Kimijima I; Abe R; Kanno M; Katagata N; Hara K; Watanabe T; Tsuchiya A
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2329-35. PubMed ID: 9815631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours.
    Crook T; Brooks LA; Crossland S; Osin P; Barker KT; Waller J; Philp E; Smith PD; Yulug I; Peto J; Parker G; Allday MJ; Crompton MR; Gusterson BA
    Oncogene; 1998 Oct; 17(13):1681-9. PubMed ID: 9796697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study.
    Armes JE; Egan AJ; Southey MC; Dite GS; McCredie MR; Giles GG; Hopper JL; Venter DJ
    Cancer; 1998 Dec; 83(11):2335-45. PubMed ID: 9840533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA-associated breast cancer: absence of a characteristic immunophenotype.
    Robson M; Rajan P; Rosen PP; Gilewski T; Hirschaut Y; Pressman P; Haas B; Norton L; Offit K
    Cancer Res; 1998 May; 58(9):1839-42. PubMed ID: 9581822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
    Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
    Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.
    Pinilla SM; Honrado E; Hardisson D; Benítez J; Palacios J
    Breast Cancer Res Treat; 2006 Sep; 99(1):85-90. PubMed ID: 16541313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers.
    Krajewski S; Thor AD; Edgerton SM; Moore DH; Krajewska M; Reed JC
    Clin Cancer Res; 1997 Feb; 3(2):199-208. PubMed ID: 9815673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histopathology of BRCA1- and BRCA2-associated breast cancer.
    Honrado E; Benítez J; Palacios J
    Crit Rev Oncol Hematol; 2006 Jul; 59(1):27-39. PubMed ID: 16530420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in exons 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma.
    van Slooten HJ; van De Vijver MJ; Borresen AL; Eyfjörd JE; Valgardsdóttir R; Scherneck S; Nesland JM; Devilee P; Cornelisse CJ; van Dierendonck JH
    J Pathol; 1999 Dec; 189(4):504-13. PubMed ID: 10629550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.